All articles by
Lupin Launches World’s First Fixed-dose Triple Combination Drug, Vilfuro-G for COPD Management in India
This milestone follows the approval granted by the Drug Controller General of India for the Dry Powder Inhaler (DPI) product
Flywheel partners with Microsoft and Nvidia to boost AI development platform
Flywheel’s new SaaS platform is integrated with Nvidia MONAI, a part of the Nvidia AI Enterprise software platform, and Azure Machine Learning Studio, to enable the development and deployment of production-grade AI applications
Boehringer Ingelheim snaps up T3 Pharmaceuticals for $508m
Boehringer Ingelheim said its immune-modulatory cancer medicines will benefit from T3 Pharma’s advanced technology, supporting the company’s oncology plan of improving the lives of cancer patients
XEOMIN receives three new therapeutic indications in Australia
This marks a significant milestone as XEOMIN is the first approved neurotoxin for the treatment of this condition in the Australian market
Fresenius Medical Care resolves dispute with US govt over Tricare payments
As a result of the settlement, Fresenius Medical Care has projected a net positive impact on operating income for Q4 2023 at around €175m
Texas AG goes court against Pfizer over adulterated Quillivant drug for ADHD kids
In the complaint, filed in Harrison County, Texas District Court, Paxton accused Pfizer and Tris Pharma of manipulating quality-control testing for the medication Quillivant XR between 2012 and 2018
Zevra Therapeutics wraps up acquisition of Acer Therapeutics
Zevra aims to advance in the development and commercialisation of treatments for rare diseases and support patient communities with limited or no existing therapeutic options
FDA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome
NeoImmuneTech’s NT-I7 has shown potential in nonclinical studies to address the immunosuppressive effects of ARS
Almirall’s Ebglyss gets EC approval for treatment of atopic dermatitis
Almirall will begin the commercial launch of the drug in Germany, with plans to progressively extend the rollout to additional European countries throughout 2024
BeiGene secures EC approval for Brukinsa to treat Follicular Lymphoma
The approval was based on the positive results from ROSEWOOD Phase 2 study in which Brukinsa plus the obinutuzumab achieved higher overall response rate compared to obinutuzumab alone